regulatory
confidence high
sentiment negative
materiality 0.85
Cara Therapeutics gets Nasdaq deficiency for equity ($707K vs $2.5M min); also faces bid-price delisting risk
Tvardi Therapeutics, Inc.
- Stockholders' equity of $707,000 at Sep 30, 2024 is below Nasdaq's $2.5 million minimum.
- Company has 45 days (by Jan 3, 2025) to submit a compliance plan; Nasdaq may grant up to 180-day extension.
- Also has outstanding minimum bid price deficiency; must close at $1.00+ for 10 consecutive days by Jan 27, 2025.
- Listing remains effective pending compliance; company evaluating options including reverse stock split.